Workflow
智能用电产品及系统
icon
Search documents
三星医疗(601567):双主业经营稳健,智能配用电加速出海
CMS· 2026-03-06 06:49
证券研究报告 | 公司深度报告 2026 年 03 月 06 日 三星医疗(601567.SH) 双主业经营稳健,智能配用电加速出海 中游制造/电力设备及新能源 公司经过二十余年发展,形成了智能配用电和医疗服务双主业。在国内配用电 领域,聚焦电网、发电等央国企客户,市场份额领先且较稳定。海外配用电高 景气,公司近几年重点拓展欧洲、中东、拉美等市场,深化本地化经营,海外 收入占比预计持续提升。首次覆盖,给予"增持"评级。 ❑ 风险提示:国内配用电投资不及预期、海外配电拓展不及预期、竞争加剧等。 财务数据与估值 | 会计年度 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 11463 | 14600 | 15988 | 18226 | 21506 | | 同比增长 | 26% | 27% | 9% | 14% | 18% | | 营业利润(百万元) | 2270 | 2585 | 2145 | 2341 | 3008 | | 同比增长 | 97% | 14% | -17% | ...
海兴电力首季营收净利双降拟不超2亿元回购 上市后分红累逾19亿元负债率降至23.69%
Chang Jiang Shang Bao· 2025-05-28 23:20
Core Viewpoint - The company, Haixing Electric Power, is implementing a share buyback plan to stabilize the market and boost investor confidence, with a buyback amount between 100 million and 200 million yuan, indicating a commitment to enhancing long-term value [1] Group 1: Share Buyback and Financial Performance - Haixing Electric Power announced a share buyback plan to repurchase between 2.86 million and 5.71 million shares, representing 0.59% to 1.18% of its total share capital, with a buyback price ceiling of 35 yuan per share, significantly higher than the current price of 25.98 yuan [1] - The company has a strong financial position, with cash reserves of 2.065 billion yuan and a low debt ratio of 23.69%, which has decreased year-on-year [2] - Since its listing in 2016, Haixing Electric Power has consistently paid dividends, totaling 1.965 billion yuan, with a payout ratio of 54.46% [1][2] Group 2: Revenue and Profit Trends - The company's revenue has shown consistent growth, with figures of 3.31 billion yuan, 4.2 billion yuan, and 4.717 billion yuan from 2022 to 2024, all achieving double-digit year-on-year growth [2] - However, in the first quarter of 2025, the company faced a decline in performance, with revenue dropping by 12.99% to 785 million yuan and net profit decreasing by 34.07% to 141 million yuan [3] - Despite the recent challenges, the company has maintained high investment in research and development, with R&D expenses increasing to 311 million yuan in 2024, totaling 824 million yuan over three years [3]